<DOC>
	<DOCNO>NCT00361101</DOCNO>
	<brief_summary>The purpose study determine safety activity AMD11070 HIV-infected patient carry X4-tropic virus .</brief_summary>
	<brief_title>A Study AMD11070 HIV-infected Patients Carrying X4-tropic Virus</brief_title>
	<detailed_description>AMD11070 new chemical entity inhibit HIV-1 entry bind specifically reversibly CXCR4 , coreceptor require T-tropic virus membrane fusion entry cell . The purpose study evaluate safety relative antiretroviral activity AMD11070 HIV-infected individual demonstrate X4 -tropic virus plasma . With ongoing development fusion entry inhibitor need alternative treatment option patient ( especially multidrug resistant virus ) , demonstration activity safety AMD11070 represent potentially important advance antiretroviral therapeutic . This first study determines therapeutic potential anti-CXCR4 compound HIV-infected patient . Note : Study previously suspend due non-clinical report hepatotoxicity histologic finding . Study complete .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>HIV1 infection , document licensed ELISA test kit ( confirmed Western Blot ) , HIV1 culture , HIV1 antigen , plasma HIV1 RNA , cDNA , second antibody test method ELISA acceptable alternative confirmatory test . Both antiretroviral treatmentnaïve experience patient . Treatmentexperienced patient currently antiretroviral therapy require washout period least 14 day prior study entry . Presence X4 tropic virus determine luciferase activity ≥2000 rlu HIV1 coreceptor tropism assay sample collect 56 day prior study baseline . Peripheral blood CD4+ cell count ≤200 cells/mm^3 . Plasma HIV1 RNA ≥5000 copies/ml standard assay . Laboratory value prior study entry : A . Absolute neutrophil count ( ANC ) ≥750/mm^3 . B. WBC ≥1500/mm^3 . C. Hemoglobin ≥10g/dL . D. Platelet count ≥80,000/mm^3 . E. Creatinine ≤ 1.2 x ULN . F. AST ( SGOT ) , ALT ( SGPT ) , alkaline phosphatase ≤ 1.5 x ULN . G. Total bilirubin ≤ 1.2 x ULN . Note : Except patient atazanavir indinavir screening . For patient , total bilirubin ≤ 4.0 x ULN permit . H. Serum lipase within normal limit . I. PT PTT ≤ 1.2 x ULN . J. Calcium magnesium within normal limit . Female patient reproductive potential must negative serum urine pregnancy test sensitivity least 50 mIU/ml perform within 24 hour study entry initiation protocolspecified medication.. All patient must agree participate conception process ( e.g. , active attempt become pregnant impregnate , sperm donation , vitro fertilization ) . Willingness female patient discontinue hormonal contraception 1 week prior study entry . Note : Female patient discontinue hormonal contraception prior study entry may resume hormonal contraception study day 11 . Karnofsky performance score ≥90 screening . Ability willingness patient legal guardian/representative give write informed consent . Patients know sensitivity AMD11070 excipients ( cellulose , croscarmellose , sodium stearyl fumarate , silicone dioxide , calcium phosphate dihydrate , sodium lauryl sulfate ) . Pregnancy breastfeed . Any antiretroviral treatment within 14 day prior study entry . Any immunization within 30 day prior study entry . Treatment radiation therapy cytotoxic chemotherapy agent immunomodulating agent within 30 day prior study entry . Use contraindicate prescription medication , herbal supplement , aspirin within seven day prior study entry . Use CYP3A4 inhibitor inducer , Pgp inducers inhibitor . Use CYP450 substrates allow protocol exception CYP2D6 CYP2C8 substrate . Use investigational drug ( i.e . drug approve indication ) within 30 day prior study entry . Evidence active infection acute illness kind within 14 day prior study entry , include HIVassociated opportunistic infection . Chronic diarrhea define &gt; 3 stools/day 4 week prior study entry . Documented history cardiac conduction abnormality , cardiac arrhythmia , cardiomyopathy , repolarization delay ( QTc &gt; 500msec ) history additional risk factor torsade de pointes ( e.g. , heart failure , hypokalemia ) . Active drug alcohol use dependence , opinion site investigator , would interfere adherence study requirement . Any medical psychological condition might , opinion site investigator , interfere participation study put patient undue risk .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>HIV</keyword>
	<keyword>X4 tropic virus</keyword>
</DOC>